Assessment of Frequency and Reporting of Changes in Cancer Trial Design After Initiation of Patient Accrual

Por: Shepshelovich, D, Tibau, A, Molto, C, Goldvaser, H, Ocana, A, Seruga, B, Amir, E

---

Publicada: 1 ene 2019

---

---

Filiaciones:
Shepshelovich, D:
 Princess Margaret Canc Ctr, Dept Med, Div Med Oncol & Hematol, Toronto, ON, Canada

 Tel Aviv Univ, Sackler Fac Med, Dept Internal Med, Tel Aviv, Israel

Tibau, A:
 Univ Autonoma Barcelona, Hosp Santa Creu & Sant Pau, Oncol Dept, Barcelona, Spain

Molto, C:
 Univ Autonoma Barcelona, Hosp Santa Creu & Sant Pau, Oncol Dept, Barcelona, Spain

Goldvaser, H:
 Princess Margaret Canc Ctr, Dept Med, Div Med Oncol & Hematol, Toronto, ON, Canada

 Tel Aviv Univ, Sackler Fac Med, Dept Oncol, Tel Aviv, Israel

Ocana, A:
 Albacete Univ Hosp, Reg Ctr Biomed Res CRIB, Translat Oncol Lab, Res Unit, Albacete, Spain

 Castilla La Mancha Univ, Ctr Invest Biomed Red Canc CIBERONC, Albacete, Spain

Seruga, B:
 Inst Oncol Ljubljana, Dept Med Oncol, Ljubljana, Slovenia

Amir, E:
 Princess Margaret Canc Ctr, Dept Med, Div Med Oncol & Hematol, Toronto, ON, Canada

 Univ Toronto, Dept Med, Toronto, ON, Canada